Dental Implants Market

The dental implants market is worth USD 6,235.0 million in 2025 and reaches USD 11,109.5 million by 2035, compounding at 5.95% a year. The figure is built bottom-up: roughly 21.5 million dental implants placed in 2025 across premium implant systems, value and challenger implant systems, abutments and prosthetic components, and guided surgery and digital planning, at an average realised manufacturer price of USD 290 per implant including associated components, triangulated against procedure volumes, manufacturer disclosures and national procurement data. Implants placed grow 6.8% a year as ageing populations and wider access increase treatment, while realised price per implant falls 0.8% a year as value brands and government procurement in China pressure prices. This study sits within our dental care coverage and follows the published Douglas Insights methodology.

What did China’s price cuts do to the implant market?

They cut prices dramatically and expanded volume sharply, offering a preview of how government purchasing can reshape a premium medical device market. In 2023 China introduced a national volume based procurement programme for dental implants, in which manufacturers bid for access to public hospital demand by offering steep price reductions in exchange for guaranteed volumes, alongside caps on the fees dentists could charge for the procedure. Average implant prices in the programme fell by more than half, and procedure costs to patients dropped substantially. The effect was a surge in implant treatment as the procedure became affordable to many more people, while manufacturers, including premium foreign brands, faced much lower prices in a large market. Some manufacturers gained share by accepting lower prices in return for volume, and domestic Chinese manufacturers expanded. The lesson for the global market is that the price of implants is not fixed by technology but heavily influenced by purchasing structures, and that lower prices can unlock large latent demand. The exclusive chapter of this report models price and volume elasticity by market, since this relationship now shapes the outlook.

What does this market include?

This study covers dental implants and closely associated components. Premium implant systems cover implants from established brands with extensive clinical research, advanced surfaces and broad product ranges. Value and challenger implant systems cover lower priced implants from newer and regional manufacturers, including many that have grown rapidly. Abutments and prosthetic components cover the connecting parts and components that attach the crown or bridge to the implant. Guided surgery and digital planning cover surgical guides, planning software and digital workflow tools sold by implant manufacturers. Dental crowns and bridges and the materials used to make them, dental equipment such as imaging and chairs covered in our separate dental equipment coverage, bone graft materials sold separately and the fees charged by dentists sit outside the boundary. Value is measured at manufacturer realised price.

Why is the market splitting into premium and value tiers?

Because many dentists and patients are willing to trade the reputation and clinical evidence of premium brands for significantly lower prices, and value manufacturers have improved enough to make that trade acceptable. Premium implant companies built their positions on decades of clinical research, proprietary surfaces that promote bone integration, comprehensive product systems and education programmes, and they charge accordingly. Over the past two decades, a large number of value and challenger manufacturers, particularly from South Korea, Israel, Europe and increasingly China, have offered implants with similar designs at much lower prices, and many have built strong reputations and large volumes. At the same time, dental service organisations, groups of practices that buy centrally, have gained purchasing power and push for lower costs. The market has therefore split into a premium tier, where brands compete on evidence, innovation and service, and a value tier, where price and reliability matter most, with the value tier growing faster in volume. Premium manufacturers have responded by acquiring or launching value brands to serve both tiers. This tiering explains why realised price per implant is flat to declining even as the market grows.

What drives demand?

The first driver is ageing populations and tooth loss. Older people are more likely to have lost teeth, and implants are increasingly the preferred replacement over dentures and bridges.

The second driver is affordability and access. Lower prices from value brands and purchasing programmes make implants accessible to many more patients, as China’s experience showed.

The third driver is digital dentistry. Digital scanning, planning and guided surgery make implant treatment more predictable and efficient, encouraging more dentists to place implants.

The fourth driver is dental service organisations and training. Group practices and more general dentists trained to place implants expand treatment capacity.

What restrains the market?

Three restraints are modelled. Cost and reimbursement are the first: implants remain expensive for patients, are often not covered or only partly covered by insurance and public health systems, and demand is sensitive to economic conditions. Price pressure is second: value brands, procurement programmes and group purchasing push prices down, squeezing manufacturer revenue per implant. Clinical complications are third: implant failure and peri-implantitis, an inflammatory condition around implants, can occur, and concerns about complications and the need for skilled placement limit adoption among some dentists and patients.

Which categories carry the revenue?

Premium implant systems lead with 42% of 2025 revenue, USD 2,618.7 million, reflecting higher prices despite a smaller share of volume. Value and challenger implant systems hold 34%, USD 2,119.9 million, and grow fastest in volume as price conscious buyers shift. Abutments and prosthetic components account for 16%, USD 997.6 million, sold with implants and increasingly customised through digital design. Guided surgery and digital planning contribute 8%, USD 498.8 million, growing with digital dentistry. Each category is modelled through 2035 by region.

Where are implants placed?

Europe leads with 34% of 2025 revenue, USD 2,119.9 million, growing 5.2% a year, with high implant usage in Germany, Italy, Spain and elsewhere. North America holds 28%, USD 1,745.8 million, at 5.4%, driven by ageing populations, dental service organisations and cosmetic demand. Asia Pacific holds 28%, USD 1,745.8 million, and grows fastest at 7.1%, driven by rapidly rising volumes in China after procurement reforms, very high implant usage in South Korea, and growth in Japan, India and Southeast Asia. Latin America contributes USD 311.8 million at 6.4%, led by Brazil, the Middle East USD 187.1 million at 7.0% and Africa USD 124.7 million at 6.6%. Six regional models sum to the global figure, with country tables in the Excel model.

Who makes dental implants?

Straumann is the global leader, with premium and value brands and a strong position in digital dentistry. Nobel Biocare, part of Envista, Dentsply Sirona, and ZimVie, among others, supply premium and mid tier implants. Osstem Implant of South Korea, taken private and among the largest manufacturers by volume, together with Dentium and other Korean makers, compete strongly on value. MegaGen, Neodent, owned by Straumann, and many regional manufacturers in Europe, Israel and China supply the value tier, and Chinese domestic manufacturers have grown with procurement reforms. The competitive chapter profiles each manufacturer’s brands, price positioning, product range, digital capability and regional presence.

How are implants priced?

Average realised manufacturer price is USD 290 per implant in 2025, varying widely. Premium implants from leading brands command several times the price of value implants, and prices differ substantially between countries. In China, procurement programmes set much lower prices than in Western markets. Implants are often sold with abutments and components as systems, and manufacturers offer bundles, education and digital services. Dental service organisations negotiate volume pricing. Because the mix shifts toward value implants and procurement lowers prices in major markets, the average realised price per implant falls slightly, which is the reason for the negative price leg, even as premium brands maintain pricing in their segment. The pricing chapter publishes price bands by tier and region.

How do the scenarios diverge by 2035?

The base case carries 6.8% growth in implants placed and a 0.8% annual price decline for a 5.95% revenue CAGR and USD 11,109.5 million in 2035. The price-compression scenario, in which procurement programmes spread to more countries and value brands take more share, sets the legs at 7.4% and minus 3.0%, landing near USD 9,390 million, with more implants but lower revenue per implant. The premium-resilience scenario, in which demand grows strongly and premium brands maintain pricing through digital differentiation, sets them at 7.6% and 0.8%, carrying the market past USD 14,030 million. Each 1-point change in implant growth moves the 2035 figure by roughly USD 1,030 million.

Which rules and standards apply?

Three layers matter. Medical device regulation comes first: dental implants are regulated medical devices requiring approval, with requirements for materials, biocompatibility and clinical evidence, and stricter European medical device rules have increased compliance costs. Procurement and pricing policy is second: government purchasing programmes, such as China’s volume based procurement, and national pricing rules directly affect implant prices and volumes. Reimbursement and insurance are third: whether public health systems and private insurers cover implants, and to what extent, shapes patient demand. The regulatory chapter maps these requirements by jurisdiction.

Will volume based procurement spread beyond China?

China’s experience raises the question of whether other countries will adopt similar purchasing programmes, which would reshape the global implant market further. Several factors suggest partial spread. Governments seeking to expand access to dental care while controlling costs may see volume based procurement as a model, and some countries in Asia and elsewhere have explored centralised purchasing of medical devices. The dramatic increase in implant treatment in China after prices fell demonstrates latent demand that lower prices can unlock. However, in many Western markets, implants are paid largely privately rather than through public systems, so government purchasing has less leverage, and dental care is often delivered through independent practices rather than public hospitals. As a result, the most likely outcome is that procurement driven price reductions remain concentrated in markets with strong public purchasing, while private markets see gradual price pressure from value brands and dental service organisations. The model reflects moderate spread, with the price compression scenario capturing a faster, wider adoption.

Douglas Exclusive: the price and volume elasticity model

This report models, by market, the relationship between implant prices and treatment volumes, the effect of procurement programmes, the share of premium and value implants, and patient affordability, converting demographic and pricing assumptions into implant volumes and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from implants: implant procedure volumes by region, premium and value mix, procurement programme effects, components per implant, and realised manufacturer prices from company disclosures and procurement data, with crowns and bridges, dental equipment, separately sold bone grafts and dentist fees excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.